相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Cancer statistics, 2020
Rebecca L. Siegel et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2020)
Phase II study of oral ridaforolimus in patients with metastatic and/or locally advanced recurrent endometrial cancer: NCIC CTG IND 192.
H. Mackay et al.
JOURNAL OF CLINICAL ONCOLOGY (2017)
Targeting mTOR pathway in gynecological malignancies: Biological rationale and systematic review of published data
Loay Kassem et al.
CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY (2016)
A randomized phase II non-comparative study of PF-04691502 and gedatolisib (PF-05212384) in patients with recurrent endometrial cancer
Josep Maria del Campo et al.
GYNECOLOGIC ONCOLOGY (2016)
Randomized Phase II Trial of Ridaforolimus in Advanced Endometrial Carcinoma
Amit M. Oza et al.
JOURNAL OF CLINICAL ONCOLOGY (2015)
Phase II Study of Everolimus and Letrozole in Patients With Recurrent Endometrial Carcinoma
Brian M. Slomovitz et al.
JOURNAL OF CLINICAL ONCOLOGY (2015)
Molecular Determinants of Outcome With Mammalian Target of Rapamycin Inhibition in Endometrial Cancer
Helen J. Mackay et al.
CANCER (2014)
Phase II study of oral ridaforolimus in women with recurrent or metastatic endometrial cancer
Daliah Tsoref et al.
GYNECOLOGIC ONCOLOGY (2014)
Temsirolimus with or without megestrol acetate and tamoxifen for endometrial cancer: A gynecologic oncology group study
Gini F. Fleming et al.
GYNECOLOGIC ONCOLOGY (2014)
Ridaforolimus as a single agent in advanced endometrial cancer: results of a single-arm, phase 2 trial
N. Colombo et al.
BRITISH JOURNAL OF CANCER (2013)
Everolimus as second- or third-line treatment of advanced endometrial cancer: ENDORAD, a phase II trial of GINECO
I. Ray-Coquard et al.
BRITISH JOURNAL OF CANCER (2013)
Integrated genomic characterization of endometrial carcinoma
Gad Getz et al.
NATURE (2013)
The PI3K/AKT/mTOR Pathway as a Therapeutic Target in Endometrial Cancer
Brian M. Slomovitz et al.
CLINICAL CANCER RESEARCH (2012)
Randomized phase Ill noninferiority trial of first line chemotherapy for metastatic or recurrent endometrial carcinoma: A Gynecologic Oncology Group study
D. Miller et al.
GYNECOLOGIC ONCOLOGY (2012)
Phase II Study of Temsirolimus in Women With Recurrent or Metastatic Endometrial Cancer: A Trial of the NCIC Clinical Trials Group
Amit M. Oza et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
A Phase 2 Study of the Oral Mammalian Target of Rapamycin Inhibitor, Everolimus, in Patients With Recurrent Endometrial Carcinoma
Brian M. Slomovitz et al.
CANCER (2010)
One- and two-stage designs for stratified phase II clinical trials
WB London et al.
STATISTICS IN MEDICINE (2005)
Phase II study of medroxyprogesterone acetate plus tamoxifen in advanced endometrial carcinoma: a Gynecologic Oncology Group study
CW Whitney et al.
GYNECOLOGIC ONCOLOGY (2004)
Phase II trial of alternating courses of megestrol acetate and tamoxifen in advanced endometrial carcinoma: a Gynecologic Oncology Group study
JV Fiorica et al.
GYNECOLOGIC ONCOLOGY (2004)
分享论文
